Several in vivo results from other researchers illustrated that many types of agents display a nephroprotective effect in ischemia–reperfusion-induced AKI by regulating TLR4/NF-κB pathway-mediated inflammation in the kidneys11,29–31. The gene discussed is NFKB1; the disease is ischemia.